Braun Stacey Associates Boosted Its Target (TGT) Position; 2 Analysts Bullish ChemoCentryx, Inc. (CCXI)

Target Corporation (NYSE:TGT) Logo

Among 2 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx has $2400 highest and $22 lowest target. $23’s average target is 242.26% above currents $6.72 stock price. ChemoCentryx had 4 analyst reports since March 12, 2019 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, March 12 by H.C. Wainwright. The rating was upgraded by FBR Capital to “Buy” on Wednesday, March 27. See ChemoCentryx, Inc. (NASDAQ:CCXI) latest ratings:

06/06/2019 Broker: BidaskScore Rating: Buy Downgrade
06/06/2019 Broker: Inc. – Common Stock Rating: Raymond James New Target: $24.0000 17.0000
27/03/2019 Broker: FBR Capital Old Rating: Neutral New Rating: Buy Old Target: $12.5 New Target: $22 Upgrade
12/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $23 Maintain

Braun Stacey Associates Inc increased Target Corp (TGT) stake by 3.76% reported in 2019Q1 SEC filing. Braun Stacey Associates Inc acquired 5,207 shares as Target Corp (TGT)’s stock rose 14.18%. The Braun Stacey Associates Inc holds 143,648 shares with $11.53 million value, up from 138,441 last quarter. Target Corp now has $43.14B valuation. The stock increased 2.00% or $1.65 during the last trading session, reaching $84.21. About 4.71 million shares traded. Target Corporation (NYSE:TGT) has risen 6.39% since August 17, 2018 and is uptrending. It has outperformed by 6.39% the S&P500. Some Historical TGT News: 15/03/2018 – Cramer argues that the powers of Amazon, Walmart and Target coalesced to push Toys R Us into bankruptcy; 06/03/2018 – Target’s Same-Store Sales Surpass Expectations; 23/05/2018 – Target 1Q Comparable Average Transaction Amount Fell 0.6%; 03/05/2018 – SALLY BEAUTY HOLDINGS INC – AARON JOINS SALLY BEAUTY HOLDINGS FROM TARGET CORPORATION; 28/03/2018 – Companies interested in the locations include Target, Aldi, Big Lots and some real estate investment trusts; 23/05/2018 – Target 1Q Traffic Rose 3.7%; 23/03/2018 – Target And Kroger In Merger Talks: Report — MarketWatch; 05/04/2018 – Target settles claims it screened blacks, Hispanics out of jobs; 23/05/2018 – TARGET CORP – QTRLY COMPARABLE SALES GROWTH OF 3.0 PERCENT; 06/03/2018 – Target: January Comparable Sales Rose More Than 4%

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $391.44 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Investors sentiment increased to 1.44 in Q1 2019. Its up 0.51, from 0.93 in 2018Q4. It is positive, as 12 investors sold ChemoCentryx, Inc. shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Dorsey Wright And holds 585 shares. Moreover, Point72 Asset Management L P has 0.03% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). State Bank Of America Corporation De stated it has 92,817 shares. Sg Americas Secs Ltd Co has 20,240 shares for 0% of their portfolio. Renaissance Techs Lc owns 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 1.13 million shares. Qs Ltd Liability Company owns 643 shares or 0% of their US portfolio. 9,979 were reported by One Trading Ltd Partnership. The New York-based Citigroup Inc has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Strs Ohio reported 0% stake. Carmignac Gestion invested in 0.32% or 1.97M shares. Wells Fargo And Mn has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Alliancebernstein L P stated it has 46,500 shares or 0% of all its holdings. Marshall Wace Llp holds 0.02% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 132,410 shares. Moreover, Sectoral Asset has 0.03% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). State Of Wisconsin Inv Board holds 30,100 shares or 0% of its portfolio.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx (CCXI) Reports Q2 Loss, Lags Revenue Estimates – Nasdaq” on August 05, 2019, also Seekingalpha.com with their article: “ChemoCentryx down 16% after Q2 revenue miss – Seeking Alpha” published on August 06, 2019, Seekingalpha.com published: “ChemoCentryx, Inc. 2019 Q2 – Results – Earnings Call Slides – Seeking Alpha” on August 06, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Seekingalpha.com and their article: “ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” published on August 06, 2019 as well as Globenewswire.com‘s news article titled: “ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019 – GlobeNewswire” with publication date: July 31, 2019.

The stock increased 3.86% or $0.25 during the last trading session, reaching $6.72. About 483,011 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has declined 28.17% since August 17, 2018 and is downtrending. It has underperformed by 28.17% the S&P500. Some Historical CCXI News: 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En

Braun Stacey Associates Inc decreased Tabula Rasa Healthcare Inc Com stake by 7,678 shares to 235,470 valued at $13.29M in 2019Q1. It also reduced Nucor Corp (NYSE:NUE) stake by 5,635 shares and now owns 29,248 shares. Eog Res Inc Com (NYSE:EOG) was reduced too.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

State Street Increased Chemocentryx (CCXI) Stake by $12.08 Million; United States Cellular (USM)’s Sentiment Is 0.91

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

State Street Corp increased Chemocentryx Inc (NASDAQ:CCXI) stake by 293.31% reported in 2019Q2 SEC filing. State Street Corp acquired 1.34M shares as Chemocentryx Inc (NASDAQ:CCXI)’s stock declined 38.33%. The State Street Corp holds 1.80M shares with $16.74 million value, up from 457,546 last quarter. Chemocentryx Inc now has $391.44M valuation. The stock increased 3.86% or $0.25 during the last trading session, reaching $6.72. About 483,011 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has declined 28.17% since August 17, 2018 and is downtrending. It has underperformed by 28.17% the S&P500. Some Historical CCXI News: 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

United States Cellular Corp (USM) investors sentiment decreased to 0.91 in Q1 2019. It’s down -0.45, from 1.36 in 2018Q4. The ratio fall, as 60 funds started new or increased stock positions, while 66 sold and decreased their positions in United States Cellular Corp. The funds in our database reported: 14.20 million shares, up from 13.85 million shares in 2018Q4. Also, the number of funds holding United States Cellular Corp in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 15 Reduced: 51 Increased: 42 New Position: 18.

Gamco Investors Inc. Et Al holds 0.71% of its portfolio in United States Cellular Corporation for 2.03 million shares. Gabelli Funds Llc owns 969,300 shares or 0.28% of their US portfolio. Moreover, Alpha Windward Llc has 0.26% invested in the company for 8,460 shares. The New York-based Quinn Opportunity Partners Llc has invested 0.25% in the stock. Acadian Asset Management Llc, a Massachusetts-based fund reported 829,713 shares.

United States Cellular Corporation provides wireless telecommunications services in the United States. The company has market cap of $3.02 billion. The Company’s wireless services include postpaid and prepaid service plans with voice, messaging, and data services; and smartphone messaging, data, and Internet services, which allow the customer to access the Web and social network sites, e-mail, text, picture, and video messaging, as well as to utilize GPS navigation, and browse and download various applications. It has a 21.65 P/E ratio. The firm also offers roaming services; machine to machine solutions and software applications in the areas of monitor and control, business automation/operations, communication, and asset management; wireless devices, such as handsets, tablets, mobile hotspots, home phones, and routers; and accessories comprising wireless basics, such as cases, screen protectors, chargers, and memory cards.

More notable recent United States Cellular Corporation (NYSE:USM) news were published by: Finance.Yahoo.com which released: “Here’s Why United States Cellular (NYSE:USM) Has A Meaningful Debt Burden – Yahoo Finance” on July 31, 2019, also Finance.Yahoo.com with their article: “The United States Cellular (NYSE:USM) Share Price Has Gained 20% And Shareholders Are Hoping For More – Yahoo Finance” published on June 11, 2019, Bizjournals.com published: “See inside the new U.S. Cellular Loft at Lambeau Field – Milwaukee Business Journal” on July 31, 2019. More interesting news about United States Cellular Corporation (NYSE:USM) were released by: Finance.Yahoo.com and their article: “All You Need To Know About United States Cellular Corporation’s (NYSE:USM) Financial Health – Yahoo Finance” published on May 01, 2019 as well as Businesswire.com‘s news article titled: “Consumers Rate U.S. Cellular Highest for Network Quality in the North Central Region in Latest J.D. Power Study – Business Wire” with publication date: July 24, 2019.

The stock increased 2.61% or $0.89 during the last trading session, reaching $34.97. About 319,467 shares traded or 33.27% up from the average. United States Cellular Corporation (USM) has risen 38.37% since August 17, 2018 and is uptrending. It has outperformed by 38.37% the S&P500. Some Historical USM News: 10/04/2018 – Fractus Files Patent Infringement Suit Against Telecom Giants AT&T, Verizon, T-Mobile and Sprint; 15/05/2018 – U.S. Cellular Presenting at JPMorgan Conference Tomorrow; 28/03/2018 U.S. Cellular to Offer New 9.7-inch iPad With Apple Pencil Support; 01/05/2018 – US Cellular 1Q EPS 52c; 10/05/2018 – U.S. Cellular Presenting at JPMorgan Conference May 16; 01/05/2018 – U.S. CELLULAR REAFFIRMS YR OPER REV., ADJ. EBITDA, CAPEX VIEWS; 16/05/2018 – UNITED STATES CELLULAR SAYS ON MAY 10, CO ENTERED INTO $300 MLN CREDIT AGREEMENT – SEC FILING; 01/05/2018 – US Cellular 1Q Rev $942M; 15/05/2018 – TDS and U.S. Cellular To Webcast Annual Meetings Of Shareholders; 01/05/2018 – US Cellular Backs 2018 Rev $3.85B-$4.05B

Investors sentiment increased to 1.44 in 2019 Q1. Its up 0.51, from 0.93 in 2018Q4. It is positive, as 12 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Legal & General Group Public Ltd Company has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). 46,500 are owned by Alliancebernstein Lp. Carmignac Gestion owns 1.97M shares. Fernwood Inv Mgmt Ltd Liability Corporation has 10,000 shares. Acadian Asset Mgmt Ltd Liability Corporation reported 775,123 shares. Tiaa Cref Inv Management Ltd Liability Co holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 288,597 shares. Wells Fargo Mn holds 127,125 shares or 0% of its portfolio. State Common Retirement Fund accumulated 25,400 shares. Moreover, Alps Advisors has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Clarivest Asset Ltd Liability Co reported 51,400 shares. Swiss Retail Bank reported 0% stake. Arrowstreet Cap Partnership accumulated 324,748 shares. Fmr Ltd holds 0.01% or 5.77 million shares. Invesco, Georgia-based fund reported 148,988 shares. Bancshares Of Montreal Can owns 123,643 shares for 0% of their portfolio.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $391.44 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

State Street Corp decreased Caci Intl Inc (NYSE:CACI) stake by 164,333 shares to 620,841 valued at $127.02M in 2019Q2. It also reduced Mirati Therapeutics Inc (NASDAQ:MRTX) stake by 269,916 shares and now owns 1.14M shares. Boeing Co (NYSE:BA) was reduced too.

Among 2 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx has $2400 highest and $22 lowest target. $23’s average target is 242.26% above currents $6.72 stock price. ChemoCentryx had 4 analyst reports since March 12, 2019 according to SRatingsIntel. As per Tuesday, March 12, the company rating was maintained by H.C. Wainwright. The stock has “Buy” rating by FBR Capital on Wednesday, March 27.

United States Cellular Corporation (NYSE:USM) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

As Tri Continental (TY) Valuation Were Volatile, Holder Blue Bell Private Wealth Management Lowered Its Stake; Bvf Decreased Its Chemocentryx (CCXI) Position by $67.90 Million; Share Value Declined

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Blue Bell Private Wealth Management Llc decreased its stake in Tri Continental Corp (TY) by 3.21% based on its latest 2019Q1 regulatory filing with the SEC. Blue Bell Private Wealth Management Llc sold 18,628 shares as the company’s stock 0.00% . The institutional investor held 561,309 shares of the company at the end of 2019Q1, valued at $14.76 million, down from 579,937 at the end of the previous reported quarter. Blue Bell Private Wealth Management Llc who had been investing in Tri Continental Corp for a number of months, seems to be less bullish one the $1.42B market cap company. The stock increased 0.92% or $0.24 during the last trading session, reaching $26.39. About 40,763 shares traded. Tri-Continental Corporation (NYSE:TY) has 0.00% since August 17, 2018 and is . It has by 0.00% the S&P500.

Bvf Inc decreased its stake in Chemocentryx Inc (CCXI) by 78.1% based on its latest 2019Q1 regulatory filing with the SEC. Bvf Inc sold 5.22 million shares as the company’s stock declined 38.33% . The hedge fund held 1.46 million shares of the health care company at the end of 2019Q1, valued at $20.34M, down from 6.69M at the end of the previous reported quarter. Bvf Inc who had been investing in Chemocentryx Inc for a number of months, seems to be less bullish one the $391.44 million market cap company. The stock increased 3.86% or $0.25 during the last trading session, reaching $6.72. About 441,537 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has declined 28.17% since August 17, 2018 and is downtrending. It has underperformed by 28.17% the S&P500. Some Historical CCXI News: 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA

Blue Bell Private Wealth Management Llc, which manages about $245.45 million and $214.03M US Long portfolio, upped its stake in Schwab U.S. Large (SCHX) by 4,586 shares to 277,478 shares, valued at $18.76M in 2019Q1, according to the filing.

Investors sentiment increased to 1.43 in Q1 2019. Its up 0.25, from 1.18 in 2018Q4. It improved, as 10 investors sold TY shares while 13 reduced holdings. 12 funds opened positions while 21 raised stakes. 3.95 million shares or 9.71% less from 4.38 million shares in 2018Q4 were reported. Northwestern Mutual Wealth Mngmt holds 0% or 2,031 shares in its portfolio. Royal Retail Bank Of Canada reported 0% stake. Moreover, Raymond James Financial Services Advsrs Inc has 0.04% invested in Tri-Continental Corporation (NYSE:TY) for 396,331 shares. Ancora Advsrs Ltd Liability Com holds 0.05% or 47,733 shares. Archford Cap Strategies Ltd Liability Corporation has invested 0.01% in Tri-Continental Corporation (NYSE:TY). Wesbanco Natl Bank holds 9,093 shares or 0.01% of its portfolio. Regions Fincl Corporation invested in 4,654 shares or 0% of the stock. Landscape Capital Mngmt Ltd Limited Liability Company reported 77,513 shares. First Republic Investment Incorporated reported 8,283 shares stake. Cwm Ltd Llc accumulated 0% or 935 shares. Moreover, First Advsrs Lp has 0% invested in Tri-Continental Corporation (NYSE:TY). Moreover, Wells Fargo & Mn has 0% invested in Tri-Continental Corporation (NYSE:TY). Advisory Net Lc holds 0% of its portfolio in Tri-Continental Corporation (NYSE:TY) for 328 shares. Hudock Cap Group Ltd Liability Company invested 0.01% of its portfolio in Tri-Continental Corporation (NYSE:TY). Cls Invs Ltd Liability Corporation holds 0% in Tri-Continental Corporation (NYSE:TY) or 78 shares.

More notable recent Tri-Continental Corporation (NYSE:TY) news were published by: Seekingalpha.com which released: “Tri-Continental declares $0.265 dividend – Seeking Alpha” on May 24, 2019, also Finance.Yahoo.com with their article: “Is The Liberty Braves Group (BATRA) A Good Stock To Buy? – Yahoo Finance” published on May 03, 2019, Seekingalpha.com published: “Global stocks downgraded by Morgan Stanley as growth slows – Seeking Alpha” on July 08, 2019. More interesting news about Tri-Continental Corporation (NYSE:TY) were released by: Seekingalpha.com and their article: “Tri-Continental declares $0.24 dividend – Seeking Alpha” published on March 08, 2019 as well as Businesswire.com‘s news article titled: “Tri-Continental Corporation Declares Fourth Quarter Distribution – Business Wire” with publication date: November 23, 2018.

Investors sentiment increased to 1.44 in Q1 2019. Its up 0.51, from 0.93 in 2018Q4. It increased, as 12 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Hong Kong-based Fosun Intl has invested 0.08% in ChemoCentryx, Inc. (NASDAQ:CCXI). Ny State Common Retirement Fund reported 25,400 shares. Aqr Capital Mngmt Lc holds 22,364 shares or 0% of its portfolio. Prtn Ltd Liability holds 0.02% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 19,820 shares. Sio Capital Management Limited Com stated it has 530,175 shares or 1.99% of all its holdings. Prudential Fincl reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Metropolitan Life Insur Com has invested 0.01% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Public Employees Retirement Of Ohio owns 99,284 shares for 0.01% of their portfolio. 81,534 were reported by Matarin Cap Mngmt Lc. Alliancebernstein Lp owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 46,500 shares. Acadian Asset Mngmt Limited reported 0.05% stake. National Bank & Trust Of America De holds 92,817 shares or 0% of its portfolio. Proshare Advsr Ltd Limited Liability Company invested in 0% or 19,606 shares. 643 were accumulated by Qs Investors Limited Liability. D E Shaw stated it has 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI).

Bvf Inc, which manages about $999.89 million and $893.07 million US Long portfolio, upped its stake in Ac Immune Sa by 5.23M shares to 7.46M shares, valued at $37.65M in 2019Q1, according to the filing. It also increased its holding in Vical Inc by 993,211 shares in the quarter, for a total of 2.28M shares, and has risen its stake in Arcus Biosciences Inc.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Seekingalpha.com which released: “ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2019 Results – Earnings Call Transcript – Seeking Alpha” on August 06, 2019, also Nasdaq.com with their article: “ChemoCentryx (CCXI) Reports Q2 Loss, Lags Revenue Estimates – Nasdaq” published on August 05, 2019, Seekingalpha.com published: “ChemoCentryx down 16% after Q2 revenue miss – Seeking Alpha” on August 06, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Globenewswire.com and their article: “ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019 – GlobeNewswire” published on July 31, 2019 as well as Seekingalpha.com‘s news article titled: “InflaRx downdraft engulfs ChemoCentryx, down 28% premarket – Seeking Alpha” with publication date: June 05, 2019.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

Inflarx NV (NASDAQ:IFRX) Short Interest Update

Inflarx NV (NASDAQ:IFRX) was the target of a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 1,569,000 shares, a growth of 13.0% from the June 30th total of 1,389,100 shares. Based on an average trading volume of 1,810,000 shares, the days-to-cover ratio is presently 0.9 days. Approximately 10.3% of the shares of the company are short sold.

IFRX stock opened at $2.56 on Friday. The business’s 50 day simple moving average is $3.02 and its 200 day simple moving average is $26.89. Inflarx has a 1-year low of $2.45 and a 1-year high of $53.10. The firm has a market capitalization of $68.55 million, a PE ratio of -1.83 and a beta of -1.53.

Inflarx (NASDAQ:IFRX) last issued its quarterly earnings data on Thursday, May 23rd. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.19. As a group, research analysts predict that Inflarx will post -2.09 EPS for the current fiscal year.

A number of research firms recently weighed in on IFRX. SunTrust Banks lowered Inflarx from a “buy” rating to a “hold” rating and decreased their target price for the stock from $55.00 to $5.00 in a report on Wednesday, June 5th. Leerink Swann lowered Inflarx from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 5th. JPMorgan Chase & Co. lowered Inflarx from an “overweight” rating to an “underweight” rating and decreased their target price for the stock from $67.00 to $9.00 in a report on Wednesday, June 5th. Guggenheim lowered Inflarx from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $65.00 to $6.00 in a report on Wednesday, June 5th. Finally, ValuEngine raised Inflarx from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $15.66.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Redmile Group LLC grew its holdings in Inflarx by 7.2% in the 1st quarter. Redmile Group LLC now owns 2,182,638 shares of the company’s stock valued at $82,482,000 after buying an additional 147,238 shares in the last quarter. Morgan Stanley grew its holdings in Inflarx by 454.5% in the 2nd quarter. Morgan Stanley now owns 337,247 shares of the company’s stock valued at $1,066,000 after buying an additional 276,424 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Inflarx in the 2nd quarter valued at $884,000. FMR LLC acquired a new position in Inflarx in the 1st quarter valued at $9,609,000. Finally, Acadian Asset Management LLC acquired a new position in Inflarx in the 2nd quarter valued at $445,000. 57.02% of the stock is currently owned by hedge funds and other institutional investors.

Inflarx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

See Also: Why is the price target of stocks important?

Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Global Hidradenitis Suppurativa Treatment Market Report, History and Forecast 2014-2025, Breakdown Data by Companies, Key Regions, Types and Application

In this report, the Global Hidradenitis Suppurativa Treatment market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Global Hidradenitis Suppurativa Treatment market has been broken down by major regions, with complete market estimates on the basis of products/applications on a regional basis.

Browse full research report at https://www.crystalmarketreport.com/global-hidradenitis-suppurativa-treatment-market-report-history-and-forecast-2014-2025-breakdown-data-by-companies-key-regions-types-and-application

Crystal Market Reports

Summary

Hidradenitis suppurativa is a rare, inflammatory skin condition that begins as small and painful pimples on the skin. This medical condition is most common between the ages of 20-40 years. Prevalence of hidradenitis suppurativa is three times more common in females than in males.

Considering the global scenario of the market, North America holds the largest market share due to various factors such as increasing cases of skin diseases and related medical complications.

In 2018, the global Hidradenitis Suppurativa Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% between 2019 and 2025.

This report studies the Hidradenitis Suppurativa Treatment market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter’s Five Forces Analysis.

This report focuses on the global top players, covered

GlaxoSmithKline

Johnson & Johnson

Merck

Pfizer

AbbVie

Allergan

AstraZeneca

Market segment by Regions/Countries, this report covers

North America

Europe

China

Rest of Asia Pacific

Central & South America

Middle East & Africa

Market segment by Type, the product can be split into

Medications

Surgery

Others

Market segment by Application, the market can be split into

Hospitals

Clinics

Others

The study objectives of this report are:

To study and forecast the market size of Hidradenitis Suppurativa Treatment in global market.

To analyze the global key players, SWOT analysis, value and global market share for top players.

To define, describe and forecast the market by type, end use and region.

To analyze and compare the market status and forecast among global major regions.

To analyze the global key regions market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends and factors driving or inhibiting the market growth.

To analyze the opportunities in the market for stakeholders by identifying the high growth segments.

To strategically analyze each submarket with respect to individual growth trend and their contribution to the market

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Hidradenitis Suppurativa Treatment are as follows:

History Year: 2014-2018

Base Year: 2018

Estimated Year: 2019

Forecast Year 2019 to 2025

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders

Raw material suppliers

Distributors/traders/wholesalers/suppliers

Regulatory bodies, including government agencies and NGO

Commercial research & development (R&D) institutions

Importers and exporters

Government organizations, research organizations, and consulting firms

Trade associations and industry bodies

End-use industries

Available Customizations

With the given market data, QYResearch offers customizations according to the company’s specific needs. The following customization options are available for the report:

Further breakdown of Hidradenitis Suppurativa Treatment market on basis of the key contributing countries.

Detailed analysis and profiling of additional market players.

Browse full research report at https://www.crystalmarketreport.com/global-hidradenitis-suppurativa-treatment-market-report-history-and-forecast-2014-2025-breakdown-data-by-companies-key-regions-types-and-application

Reasons to Buy This Research Report

About Crystal Market Reports

Crystal Market Reports is a distributor of market research spanning 160 industries. Our extensive database consists of over 400,000 quality publications sourced from 400 plus publishers, this puts our research specialists in the unique position of been able to offer truly unbiased advice on what research provides the most valuable insights.

Contact Info.:-

Address: 90 State Street
Suite 700 Albany
New York 12207
Email: [email protected]
Web: https://www.crystalmarketreport.com


Post Views:
9

Source link

Upcoming events – Rare disease data due from Chemocentryx and Sanofi

Welcome to your weekly roundup of approaching clinical readouts. Chemocentryx is expected to report phase III results with its lead project, avacopan, in the fourth quarter. The drug inhibits the C5a receptor which is part of the complement system involved in inflammation; however, hopes are not high for this approach after the recent failure of Inflarx’s similarly acting IFX-1.

Chemocentryx is taking aim at patients with antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV), a rare autoimmune disease where the complement pathway is overactivated, causing destruction of small blood vessels, which leads to organ damage and failure.

The current standard of care for AAV includes high dose steroids plus rituximab or cyclophosamide. However, these are not ideal, with steroids causing extensive immunosuppression; indeed over 50% of mortality within the first year of diagnosis is attributed to infection.

Chemocentryx’s trial, Advocate, has enrolled 331 patients  from the US, Europe and Japan. Rituximab or cyclophosphamide/azathioprine is given with either avacopan or the active comparator, the steroid prednisone at 60mg per day.

The trial has two primary endpoints; remission at 26 weeks and sustained remission at 52 weeks, assessed by the Birmingham vasculitis activity score (BVAS). Secondary endpoints include corticosteroid toxicity measures, quality of life and change in organ damage.

In Chemocentryx’s phase II Clear study two avacopan groups were tested and met non-inferiority versus placebo plus 60mg prednisone. The primary endpoint was ≥50% decrease of BVAS from baseline at week 12. Beyond the primary endpoint patients receiving avacopan also showed a significant improvement in health-related quality of life aspects and less cumulative organ damage compared to the standard of care group.

Avacopan’s 2024 sales are expected to reach $268m, according to EvaluatePharma consensus. Vifor Pharma has rights outside the US. 

However, in June Chemocentryx suffered by association as Inflarx’s anti-C5a monoclonal antibody IFX-1 failed in hidradenitis suppurativa, a skin scarring condition. Inflarx’s shares plummeted 92% while Chemocentryx’s fell 20% on the news. Avacopan is currently in phase II in hidradenitis suppurativa. Advocate will need to be a hit if any confidence is to remain in targeting C5a or its receptor.

Trial

Results?

Trial ID

Phase III Advocate

Q4 2019 (note upcoming R&D day October 1)

NCT02994927

Phase II Clear

Proportion of patients with BVAS response at Week 12: avacopan plus 20mg prednisone (86%, p=0.002 vs. SOC), and avacopan plus no steroids (81%, p=0.01 vs. SOC) compared to the high-dose steroid containing SOC group (70%)

NCT01363388

SOC: standard of care

Also looking to target part of the complement pathway is Sanofi with sutimlimab, a monocolonal antibody hitting C1s. The project is being tested in cold agglutinin disease, a rare type of autoimmune haemolytic anaemia triggered by cold temperatures in which the body’s immune system mistakenly attacks and destroys its own red blood cells.

Targeting the complement pathway is a novel approach. Current first-line therapy is B-cell-directed, including a rituximab-bendamustine combination, or rituximab monotherapy for those who cannot tolerate the former regimen. In cases of severe anaemia blood transfusions are given as a temporary measure.

Sanofi’s pivotal trial is called Cardinal. The open-label study includes 20 adult patients with haemoglobin levels <10g/dl, symptomatic disease and who have had one or more transfusion in the past six months. In part A patients received sutimlimab, which is given via intravenous infusion, for 26 weeks; part B involved a year of therapy.

The primary endpoint for part A is the percentage of patients with a response, defined as those who did not receive a blood transfusion or treatment for cold agglutinin disease; and who achieved a haemoglobin level of ≥12g/dl or whose haemoglobin increased ≥2g/dl from baseline. The primary measure for Part B is adverse events. Data are due in the fourth quarter.

A second phase III trial called Cadenza is ongoing, in patients without a prior history of blood transfusion, with a primary completion date of August 2020.

A small phase Ib trial showed a median increase in haemoglobin levels of 3.9g/dl within six weeks of treatment in seven out of 10 patients. In addition, six previously transfused patients became transfusion-free during treatment. The drug was well tolerated and there were no serious adverse events.

The project came to Sanofi through its acquisition of Bioverativ for $11.6bn last year, although that deal was focused on haemophilia therapies.

Sutimlimab sales are forecast to reach $164m in 2024, according to EvaluatePharma consensus; the drug, which has breakthrough therapy and orphan drug designation, has an NPV of $846m. 

Trial

Results?

Trial ID

Phase III Cardinal (patients with a history of blood transfusions)

 Q4 2019

NCT03347396

Phase III Cadenza (no prior history of blood transfusions)

 Primary completion August 2020

NCT03347422

Source link

10 Top Drug Sales to Watch Until 2024

Drug sales are expected to top US$1 trillion by 2024, even though a number of patents are set to expire during the period.

Even in the midst of drug pricing wars in the United States, prescription drug sales continue to rise thanks to an increase in novel medicines being developed for niche therapeutic areas.

Case in point, according to a research report from Evaluate Pharma, prescription drug sales are projected to top a staggering US$1.18 trillion by 2024, fueled by technologies such as cell and gene therapy.

Despite that astronomically high figure, a number of patents are set to expire between now and then, which could potentially damp sales.


Looking for great biotech companies?

 

Find new opportunities and valuable news in your free report

 

That being said, Evaluate Pharma states that the most profitable drug sales are ones that have been on the market for years and will continue to rake in the cash between now and 2024.

Here’s a breakdown of what those drugs are, which companies are developing them and what the sales for each are projected to reach during the forecast period.

1. Humira

Projected 2019 to 2024 sales: US$103.95 billion

Humira, which is developed by Big Pharma behemoth AbbVie (NYSE:ABBV), entered the market in 2003 and treats a wide range of conditions, including: Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ulcerative colitis and ankylosing spondylitis.

Since its launch, the drug has been additionally approved in the US and the European Union (EU) for hidradenitis suppurativa as well as uveitis in the US, EU and Japan.

According to Evaluate Pharma, Humira raked in sales of US$136.55 billion in sales from the time of its launch to 2018. Total sales are estimated to reach US$240.5 billion by 2024, which is a far cry from its runner up in terms of drug sales.

Evaluate Pharma claims Humira will become the most successful drug in the industry by 2020.

2. Lipitor

Projected 2019 to 2024 sales: US$15.76 billion

Lipitor came onto the scene in 1997 and was developed by former pharmaceutical company Warner-Lambert, which was acquired by Pfizer (NYSE:PFE) in 2000.

Lipitor is a statin cholesterol medication to treat cardiovascular disease and dyslipidemia.

Between its approval and 2018, sales of Lipitor totaled US$164.43 billion according to Evaluate Pharma data, although its sales declined after it lost patent protection in 2011. While its sales are nowhere near what they used to be, it has been, until now, the best-selling drug of all time. By 2024, total sales of Lipitor are projected to reach US180.19 billion.

3. Enbrel

Projected 2019 to 2024 sales: US$31.66 billion

Enbrel falls under Amgen’s (NASDAQ:AMGN) umbrella and was approved by the US Food and Drug Administration (FDA) in 1998 to treat rheumatoid arthritis. It was originally developed by Immunex, which Amgen acquired in 2002.

Since the first approval, Enbrel has been indicated for polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis and pediatric plaque psoriasis.

In mid-August, Amgen secured its patent win for Enbrel against Sandoz, a division of Novartis (NYSE:NVS); the decision prohibits Novartis from launching a biosimilar to Enbrel.

Between 1998 and 2018, Enbrel sales reached US108.17 billion, with total sales estimated to be US$139.83 billion by 2024.


Looking for great biotech companies?

 

Find new opportunities and valuable news in your free report

 

4. Rituxan

Projected 2019 to 2024 sales: US$24.57 billion

Rituxan was officially approved by the FDA back in 1997 by Genentech, a company that was acquired by Roche (OTCQX:RHHBY) in 2009 in a massive US$46.8 billion deal.

The drug has been approved by the regulatory agency to treat non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, microscopic polyangiitis, granulomatosis with polyangiitis and pemphigus vulgaris.

Over the course of its first 19 years on the market, sales of Rituxan generated US$111.5 billion, with total sales estimated to hit US$136.07 billion by 2024.

5. Revlimid

Projected 2019 to 2024 sales: US$69.95 billion

Revlimid is the newest drug on this list, with Celgene (NASDAQ:CELG) having received approval for the drug by the FDA in 2008.

The drug was initially indicated for multiple myeloma and has since been expanded to treat myelodysplastic syndromes and mantle cell lymphoma.

From approval to 2018, sales of Revlimid totalled US$53.69 billion. It is projected to be a bestseller in the industry between now and 2024 and is projected to reach total sales of US$123.64 billion by then. That being said, Evaluate Pharma indicates that its sales between now and 2024 will depend on the arrival of generic competition before Revlimid’s patent expires in 2022.

6. Remicade

Projected 2019 to 2024 sales: US$19.2 billion

Remicade was approved in 1998 with the FDA giving the nod to Janssen Biotech, a division of Johnson & Johnson (NYSE:JNJ).

The drug was first approved for Crohn’s disease and, since then, has been approved for a wide range of indications including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn’s disease, plaque psoriasis and pediatric ulcerative colitis.

From its approval to 2018, sales of Remicade totalled US$98 billion. The drug is expected to reach US$117.2 billion in total sales by 2024.


Looking for great biotech companies?

 

Find new opportunities and valuable news in your free report

 

7. Epogen

Projected 2019 to 2024 sales: US$7.97 billion

Amgen received approval by the FDA for Epogen in 1989 to treat anemia in connection with chronic renal failure in patients on dialysis or not on dialysis. Since that first approval, Epogen has also been indicated for certain types of cancer, such as breast, non-small cell lung, head and neck, lymphoid and cervical.

During the first few decades of approval, Epogen sales totaled US$107.9 billion with sales by 2024 projected to hit a total of US$115.87 billion.

8. Herceptin

Projected 2019 to 2024 sales: US$26.92 billion

Herceptin is another drug developed by Roche’s Genentech, and it received FDA approval in 1998. Herceptin’s first approval was to treat overexpressing breast cancer. It later received approval for HER2-positive metastatic stomach cancer.

From its launch date until 2018, sales of Herceptin touched US$87.97 billion and are projected to reach a total of US$114.89 billion by 2024.

9. Avastin

Projected 2019 to 2024 sales: US$27.14 billion

Avastin is the result of a joint development between Genentech and Roche. It received FDA approval in 2004 to treat metastatic colorectal cancer, but it has since received approval for other cancers, such as breast, lung, glioblastoma multiforme, renal cell carcinoma, cervical, ovarian, fallopian tube and peritoneal.

Sales of Avastin generated US$87.13 billion between 2004 and 2018 and are projected to hit a total of US$114.27 billion by 2024.

10. Advair

Projected 2019 to 2024 sales: US$9.41 billion

Advair is a product developed by GlaxoSmithKline (NYSE:GSK) and received approval from the FDA in 1998. The drug’s intended treatment is for asthma and chronic bronchitis.

Between 1998 and 2018, sales of Advair were US$104.2 billion, and that total number is projected to hit US$113.61 billion by 2024.

Don’t forget to follow us @INN_LifeScience for real-time news updates

Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article.


Looking for great biotech companies?

 

Find new opportunities and valuable news in your free report

 

Source link

Woman with rare skin condition reveals it feels like she’s being burned with a hot iron 

A woman with a rare skin condition, which causes open wounds which leak pus, says it feels like she is being burned with a hot iron.

Elise Axon, 25, from Dorset, appears on Discovery show The Bad Skin Clinic next week, to seek treatment for Hidradenitis Suppurativa – a rare genetic skin condition that affects just one percent of the UK population.

The condition means that she gets boil-like lumps on her legs and under her arms. At its most painful, she said that it can feel like having ‘golf balls’ under her arms, while pus and blood clots can come out of the open wounds. 

Elise exhausted all the treatments she thought were possible for her condition, including surgery. Next week she’ll appear on the show where Dr Emma Craythorne looks at how they can solve her problem.

Speaking exclusively to Femail she said: ‘It started when I was seven so I was quite  young – but I don’t remember ever not having it. I remember getting the odd boil or lump on my leg – but it got worse as I got older.

Her mother has the the same condition, so she was able to tell her what to expect straight away.

‘Medically it’s not hereditary but I have it from both sides of my family – my mum has it and so does my dad’s sister, and my cousins all on my mum’s side,’ she said.

Talking about her condition she said there are three stages, which have varied throughout her life.   

‘At stage one you get the odd boil, I use that term loosely – it’s like a lesion – this may come up and then go away.  With stage two you may have a few in one go.

‘Stage three is the worst, where you have a lot of bumps and open wounds – in one or more than one area.

As she got older it gradually spread from her legs to her arms  – and the pain became unbearable.

‘When its under my arms it feels like having a golf ball under them – trying to shut your armpit really hurts. It can also feel like a hot iron or a sharp stabbing pain – it’s what I imagine nerve pain to be like.

‘Sometimes you catch one on the side of your leg and it makes you double over in agony – creating shooting pains that make you feel sick – it takes your breath away.’

She also told Fabulous magazine: ‘When some of the lumps drain, you think it’s never going to end, there’s so much fluid coming out. Some can be very pussy, sometimes you get blood clots coming out, they can be light, dark, orange, they’re so varied.

‘The pus could drain through your clothes easily, depending on the size. 

When it comes to treatments for it she said she’s tried everything: ‘I’ve tried antibiotics, acne treatments, tropical lotions – nothing helped.

‘I even had surgery – where they removed the areas affected, but it just came back worse.’

Talking about the affects of it she said: ‘It makes me very tired. But I’m lucky that I’m quite a positive person and I don’t let my condition define who I am – so I just get on with it.

‘But I do have to be careful, I can’t wear white linen trousers, in case they start to bleed. But if I want to wear a strapless top then I will – its only going to bother someone else and not me.

She tries to stay positive about her condition, but revealed the Fabulous that some people see it as disgusting and recounted a story about how they burst under her arms one day, when she was out with friends, but a stranger thought it was ‘disgusting’. 

Talking about her time on the show she said: ‘Dr Emma is amazing, she is a book of knowledge, I thought I knew my condition well but she knew so much.

‘She started me on a treatment which suppresses parts of your immune system and  is used for lots of inflammatory diseases – so I inject myself fortnightly.

‘It made a massive improvement within a few days – my arms look a lot less inflamed and I had a really good response straight away. 

‘I wouldn’t want to come off it now as its made life that little bit easier for me – if I can keep it at this level then I’ll be happy. I could potentially be on it for the rest of my life – if it carries on working.’  

Elise has recently set up an Instagram account documenting her journey through living with HS and receiving her treatment on the show. 

She said: ‘I set it up in the hope that it might be a source of inspiration and comfort for other HS sufferers, and to help raise awareness around the condition.’

 

Source link

Wasatch Advisors Boosted Its Chemocentryx (CCXI) Position; Hsbc Holdings Plc Decreased Its Advanced Micro Devices (AMD) Position

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Wasatch Advisors Inc increased Chemocentryx Inc (CCXI) stake by 6.08% reported in 2019Q1 SEC filing. Wasatch Advisors Inc acquired 141,341 shares as Chemocentryx Inc (CCXI)’s stock declined 38.33%. The Wasatch Advisors Inc holds 2.46 million shares with $34.23M value, up from 2.32M last quarter. Chemocentryx Inc now has $382.70 million valuation. The stock decreased 3.52% or $0.24 during the last trading session, reaching $6.57. About 453,549 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has declined 28.17% since August 15, 2018 and is downtrending. It has underperformed by 28.17% the S&P500. Some Historical CCXI News: 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – ChemoCentryx 4Q Net $39.7M

Hsbc Holdings Plc decreased Advanced Micro Devices Inc (AMD) stake by 48.85% reported in 2019Q1 SEC filing. Hsbc Holdings Plc sold 534,249 shares as Advanced Micro Devices Inc (AMD)’s stock rose 13.58%. The Hsbc Holdings Plc holds 559,360 shares with $14.28 million value, down from 1.09 million last quarter. Advanced Micro Devices Inc now has $32.57B valuation. The stock decreased 0.78% or $0.24 during the last trading session, reaching $30. About 32.52M shares traded. Advanced Micro Devices, Inc. (NASDAQ:AMD) has risen 56.80% since August 15, 2018 and is uptrending. It has outperformed by 56.80% the S&P500. Some Historical AMD News: 27/04/2018 – BIOPHYTIS SA ALBPS.PA – MACUNEOS IS THE ONLY DRUG CANDIDATE IN CLINICAL DEVELOPMENT TO TREAT DRY AMD; 05/03/2018 – AUTOMODULAR – AMD CURRENTLY BELIEVES SETTLEMENT PROCEEDS IN RESPECT OF GM CLAIM MAY NOT BE RECEIVED FROM GENERAL MOTORS ON OR BEFORE MARCH 7, 2018; 26/04/2018 – Cramer says Advanced Micro Devices is a buy, but Whirlpool is a sell; 21/04/2018 – DJ Advanced Micro Devices Inc, Inst Holders, 1Q 2018 (AMD); 20/03/2018 – ADVANCED MICRO DEVICES – SECURITY ISSUES IDENTIFIED BY THIRD-PARTY RESEARCHERS ARE NOT RELATED TO AMD “ZEN” CPU ARCHITECTURE; 26/04/2018 – Dow rises about 200 points, Facebook and AMD jump after crushing earnings; 29/03/2018 – Fudzilla: AMD’s open-source Radeon Rays integrated into Unity engine; 25/04/2018 – AMD: Cryptocurrency-related Revenue Rose In First Quarter, But Headed For Decline — MarketWatch; 15/03/2018 – AMD Propels Tear-Free Gameplay Beyond the PC with Support for Radeon FreeSync™ Technology in Select Xbox One Consoles; 13/03/2018 – ADVANCED MICRO DEVICES – INVESTIGATING CTS LABS REPORT, WHICH CO GOT, TO UNDERSTAND METHODOLOGY & MERIT OF FINDINGS

Investors sentiment increased to 1.52 in 2019 Q1. Its up 0.21, from 1.31 in 2018Q4. It is positive, as 43 investors sold AMD shares while 129 reduced holdings. 102 funds opened positions while 159 raised stakes. 634.98 million shares or 5.37% more from 602.61 million shares in 2018Q4 were reported. Cornerstone Advisors invested 0% of its portfolio in Advanced Micro Devices, Inc. (NASDAQ:AMD). M&R has 480 shares. State Of New Jersey Common Pension Fund D holds 600,000 shares or 0.06% of its portfolio. Citigroup holds 0.01% or 284,368 shares. Stifel Corporation owns 243,987 shares or 0.02% of their US portfolio. Jaffetilchin Lc accumulated 11,433 shares. Jennison Ltd Limited Liability Company, New York-based fund reported 786,485 shares. Trust Of Vermont reported 78 shares stake. Wetherby Asset invested 0.05% in Advanced Micro Devices, Inc. (NASDAQ:AMD). Fred Alger Mgmt Inc holds 0.04% or 351,372 shares in its portfolio. Bb&T Ltd Liability Corporation holds 44,710 shares or 0.01% of its portfolio. Tci Wealth Advsr holds 0.03% of its portfolio in Advanced Micro Devices, Inc. (NASDAQ:AMD) for 2,348 shares. Commerce Bank reported 0.01% stake. Envestnet Asset Mngmt Inc has 18,771 shares. Baystate Wealth Mgmt Limited Liability Company holds 0% of its portfolio in Advanced Micro Devices, Inc. (NASDAQ:AMD) for 45 shares.

Hsbc Holdings Plc increased Abbott Labs (Put) (NYSE:ABT) stake by 173,600 shares to 297,100 valued at $23.75 million in 2019Q1. It also upped Ecolab Inc (Put) (NYSE:ECL) stake by 9,700 shares and now owns 14,700 shares. 3M Co (Call) (NYSE:MMM) was raised too.

Among 8 analysts covering Advanced Micro Devices (NASDAQ:AMD), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Advanced Micro Devices has $42 highest and $1700 lowest target. $33.22’s average target is 10.73% above currents $30 stock price. Advanced Micro Devices had 22 analyst reports since March 13, 2019 according to SRatingsIntel. The stock of Advanced Micro Devices, Inc. (NASDAQ:AMD) earned “Buy” rating by RBC Capital Markets on Wednesday, March 13. The firm has “Sell” rating by Morgan Stanley given on Monday, March 25. The stock of Advanced Micro Devices, Inc. (NASDAQ:AMD) has “Buy” rating given on Monday, April 8 by Bank of America. The stock of Advanced Micro Devices, Inc. (NASDAQ:AMD) has “Sell” rating given on Tuesday, March 19 by Morgan Stanley. Jefferies maintained the shares of AMD in report on Wednesday, March 20 with “Buy” rating. The firm has “Buy” rating given on Friday, June 21 by Wells Fargo. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, July 31. The company was maintained on Wednesday, March 20 by Rosenblatt.

More notable recent Advanced Micro Devices, Inc. (NASDAQ:AMD) news were published by: Seekingalpha.com which released: “AMD: High Ground Vs. Low Ground – Seeking Alpha” on August 15, 2019, also Nasdaq.com with their article: “Why Advanced Micro Devices Stock Rocketed Higher Today – Nasdaq” published on August 08, 2019, Seekingalpha.com published: “AMD target boosted for product execution – Seeking Alpha” on August 12, 2019. More interesting news about Advanced Micro Devices, Inc. (NASDAQ:AMD) were released by: Nasdaq.com and their article: “Advanced Micro Devices (AMD) 2nd Quarter Earnings: What to Expect – Nasdaq” published on July 30, 2019 as well as Benzinga.com‘s news article titled: “Crazy Action In AMD Options As Traders Take Sides In Volatile Market – Benzinga” with publication date: August 14, 2019.

Wasatch Advisors Inc decreased Zagg Inc (NASDAQ:ZAGG) stake by 208,853 shares to 1.27M valued at $11.56 million in 2019Q1. It also reduced Euronet Worldwide Inc (NASDAQ:EEFT) stake by 218,656 shares and now owns 2.39M shares. Aaon Inc (NASDAQ:AAON) was reduced too.

Investors sentiment increased to 1.44 in Q1 2019. Its up 0.51, from 0.93 in 2018Q4. It is positive, as 12 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Northern Tru Corporation has 310,007 shares for 0% of their portfolio. Wasatch owns 0.37% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 2.46 million shares. Zebra Cap Ltd Company invested in 12,853 shares. National Bank Of New York Mellon has 133,619 shares for 0% of their portfolio. Clarivest Asset Management Limited Co invested in 0.01% or 51,400 shares. Citigroup reported 6,829 shares stake. 132,410 are owned by Marshall Wace Llp. Sio Capital Management Limited owns 530,175 shares. Baker Bros Advsr Limited Partnership reported 207,029 shares stake. Ameriprise Financial holds 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 261,396 shares. Invesco Limited, a Georgia-based fund reported 148,988 shares. Dorsey Wright Assocs holds 0% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 585 shares. 55,800 were reported by Strs Ohio. Jacobs Levy Equity Mgmt Inc stated it has 51,190 shares. Employees Retirement Systems Of Ohio holds 99,284 shares or 0.01% of its portfolio.

Among 2 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx has $2400 highest and $22 lowest target. $23’s average target is 250.08% above currents $6.57 stock price. ChemoCentryx had 4 analyst reports since March 12, 2019 according to SRatingsIntel. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Buy” rating by FBR Capital on Wednesday, March 27. The company was maintained on Tuesday, March 12 by H.C. Wainwright.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx (CCXI) Reports Q2 Loss, Lags Revenue Estimates – Nasdaq” on August 05, 2019, also Seekingalpha.com with their article: “ChemoCentryx down 16% after Q2 revenue miss – Seeking Alpha” published on August 06, 2019, Finance.Yahoo.com published: “ChemoCentryx Inc (CCXI) Q2 2019 Earnings Call Transcript – Yahoo Finance” on August 08, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Nasdaq.com and their article: “ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019 – Nasdaq” published on July 31, 2019 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx, Inc. 2019 Q2 – Results – Earnings Call Slides – Seeking Alpha” with publication date: August 06, 2019.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

Uss Investment Management LTD Has Decreased Mondelez Intl (MDLZ) Position By $37.74 Million; Carmignac Gestion Has Increased Chemocentryx (CCXI) Stake

Mondelez International, Inc. (NASDAQ:MDLZ) Logo

Carmignac Gestion increased Chemocentryx Inc (CCXI) stake by 60.54% reported in 2019Q1 SEC filing. Carmignac Gestion acquired 741,210 shares as Chemocentryx Inc (CCXI)’s stock declined 38.33%. The Carmignac Gestion holds 1.97 million shares with $27.30 million value, up from 1.22 million last quarter. Chemocentryx Inc now has $381.54M valuation. The stock decreased 3.82% or $0.26 during the last trading session, reaching $6.55. About 816,080 shares traded or 60.33% up from the average. ChemoCentryx, Inc. (NASDAQ:CCXI) has declined 28.17% since August 15, 2018 and is downtrending. It has underperformed by 28.17% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting

Uss Investment Management Ltd decreased Mondelez Intl Inc (MDLZ) stake by 28.08% reported in 2019Q1 SEC filing. Uss Investment Management Ltd sold 770,172 shares as Mondelez Intl Inc (MDLZ)’s stock rose 3.58%. The Uss Investment Management Ltd holds 1.97M shares with $98.42 million value, down from 2.74 million last quarter. Mondelez Intl Inc now has $77.37 billion valuation. The stock increased 0.85% or $0.45 during the last trading session, reaching $53.65. About 3.40 million shares traded. Mondelez International, Inc. (NASDAQ:MDLZ) has risen 24.40% since August 15, 2018 and is uptrending. It has outperformed by 24.40% the S&P500. Some Historical MDLZ News: 16/04/2018 – MONDELEZ SAYS $76M 6.5% NOTES DUE 2031 TENDERED; 02/04/2018 – Mondelēz International Announces Cash Tender Offer and Consent Solicitation; 02/04/2018 – Mondelez CEO Dirk Van de Put 2017 Total Compensation $42.4M; 07/05/2018 – MONDELEZ – ISSUED $2.5 BLN IN FIXED RATE NOTES DUE 2020 , FIXED RATE NOTES DUE 2023 , FIXED RATE NOTES DUE 2028 AND FIXED RATE NOTES DUE 2048; 27/04/2018 – Mondelez: Alviti to Succeed Karen May on June 11; 01/05/2018 – MONDELEZ MAINTAINS 2018 OUTLOOK FOR ORGANIC NET REV; 01/05/2018 – Mondelez 1Q North America Rev Down 1.3%; 16/04/2018 – Mondelez Announces Early Tender Results of Its Cash Tender Offer and Consent Solicitation; 03/05/2018 – Moody’s Assigns Baa1 To Mondelez Usd $2.5 Billion Notes Offering; 11/04/2018 – Mondelēz International Reports Rapid Growth of Cocoa Life Sustainable Sourcing Program

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx (CCXI) Reports Q2 Loss, Lags Revenue Estimates – Nasdaq” on August 05, 2019, also Seekingalpha.com with their article: “ChemoCentryx down 16% after Q2 revenue miss – Seeking Alpha” published on August 06, 2019, Finance.Yahoo.com published: “ChemoCentryx Inc (CCXI) Q2 2019 Earnings Call Transcript – Yahoo Finance” on August 08, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Nasdaq.com and their article: “ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019 – Nasdaq” published on July 31, 2019 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx, Inc. 2019 Q2 – Results – Earnings Call Slides – Seeking Alpha” with publication date: August 06, 2019.

Among 2 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx has $2400 highest and $22 lowest target. $23’s average target is 251.15% above currents $6.55 stock price. ChemoCentryx had 4 analyst reports since March 12, 2019 according to SRatingsIntel. As per Tuesday, March 12, the company rating was maintained by H.C. Wainwright. FBR Capital upgraded the shares of CCXI in report on Wednesday, March 27 to “Buy” rating.

Investors sentiment increased to 1.44 in 2019 Q1. Its up 0.51, from 0.93 in 2018Q4. It increased, as 12 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. 643 are held by Qs Investors Ltd Llc. Metropolitan Life Insur Co, New York-based fund reported 42,380 shares. Retail Bank Of America De invested in 0% or 92,817 shares. Sio Cap Mgmt Llc holds 1.99% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 530,175 shares. Element Cap Ltd accumulated 0.01% or 11,906 shares. Zebra Capital Mgmt Ltd owns 0.1% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 12,853 shares. Parametric Portfolio Llc reported 55,490 shares or 0% of all its holdings. Aqr Cap Mngmt Ltd Co holds 22,364 shares. California Public Employees Retirement Sys owns 67,452 shares. Vanguard Grp Inc Inc Inc invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Jacobs Levy Equity Management owns 51,190 shares or 0.01% of their US portfolio. Art Advisors Ltd accumulated 23,876 shares. Dekabank Deutsche Girozentrale invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Ny State Common Retirement Fund owns 25,400 shares. 310,007 are owned by Northern Trust.

Carmignac Gestion decreased Albemarle Corp (NYSE:ALB) stake by 753,546 shares to 79,222 valued at $6.50 million in 2019Q1. It also reduced Qiagen N.V. stake by 210,841 shares and now owns 80,191 shares. Bristow Group Inc (NYSE:BRS) was reduced too.

Uss Investment Management Ltd increased Marsh & Mclennan Cos Inc (NYSE:MMC) stake by 12,432 shares to 2.18M valued at $204.55 million in 2019Q1. It also upped Cae Inc (NYSE:CAE) stake by 23,788 shares and now owns 6.01 million shares. Alibaba Group Hldg Ltd (NYSE:BABA) was raised too.

Investors sentiment decreased to 0.99 in Q1 2019. Its down 0.08, from 1.07 in 2018Q4. It is negative, as 54 investors sold MDLZ shares while 399 reduced holdings. 127 funds opened positions while 321 raised stakes. 1.04 billion shares or 0.32% less from 1.04 billion shares in 2018Q4 were reported. Andra Ap reported 111,100 shares. Price T Rowe Assoc Md holds 0.08% of its portfolio in Mondelez International, Inc. (NASDAQ:MDLZ) for 11.08 million shares. Loeb owns 675 shares for 0% of their portfolio. Old Second National Bank & Trust Of Aurora invested 0.13% of its portfolio in Mondelez International, Inc. (NASDAQ:MDLZ). Tci Wealth Advsr Incorporated has 0.13% invested in Mondelez International, Inc. (NASDAQ:MDLZ) for 6,102 shares. 11,877 were accumulated by Carroll Financial. Guggenheim Cap Ltd Com holds 641,049 shares. Tiedemann Limited Liability Corporation accumulated 16,018 shares. World Asset Mngmt holds 0.26% or 100,562 shares. Scotia Cap owns 73,818 shares for 0.05% of their portfolio. 346,322 were accumulated by Community Tru Invest. Credit Agricole S A stated it has 1,800 shares or 0% of all its holdings. Boston Advisors Lc holds 12,827 shares or 0.03% of its portfolio. Bank & Trust owns 1.13M shares. Invest Management Of Virginia Limited Liability Company owns 9,319 shares for 0.11% of their portfolio.

Among 3 analysts covering Mondelez Int`l (NASDAQ:MDLZ), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Mondelez Int`l has $6200 highest and $51 lowest target. $59’s average target is 9.97% above currents $53.65 stock price. Mondelez Int`l had 7 analyst reports since March 16, 2019 according to SRatingsIntel. As per Wednesday, July 31, the company rating was maintained by Buckingham Research. On Wednesday, July 31 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The stock has “Outperform” rating by Credit Suisse on Wednesday, July 31. Barclays Capital maintained Mondelez International, Inc. (NASDAQ:MDLZ) rating on Tuesday, March 19. Barclays Capital has “Buy” rating and $51 target.

More notable recent Mondelez International, Inc. (NASDAQ:MDLZ) news were published by: Nasdaq.com which released: “What’s in the Offing for Mondelez’s (MDLZ) Q2 Earnings? – Nasdaq” on July 24, 2019, also Nasdaq.com with their article: “First Week of MDLZ March 2020 Options Trading – Nasdaq” published on July 23, 2019, Nasdaq.com published: “Mondelez (MDLZ) Q2 Earnings Match Estimates – Nasdaq” on July 30, 2019. More interesting news about Mondelez International, Inc. (NASDAQ:MDLZ) were released by: Nasdaq.com and their article: “Apple (AAPL) Beats on Surprise China Numbers; Plus EA, MDLZ – Nasdaq” published on July 30, 2019 as well as Nasdaq.com‘s news article titled: “After-Hours Earnings Report for July 30, 2019 : AAPL, AMGN, GILD, MDLZ, CELG, PSA, AMD, ALL, EQR, OKE, EA, VRSK – Nasdaq” with publication date: July 30, 2019.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link